CANY
NGM

Caxton Associates (New York)’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Caxton Associates (New York)’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-32,352
Closed -$83.8K – 633
2023
Q2 		$83.8K Sell
32,352
-9,262
-22% -$33K 0.01% 458
2023
Q1 		$170K Buy
+41,614
New +$192K 0.03% 434

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caxton Associates (New York)'s NGM Position: Q3 2023 in Review

Caxton Associates (New York) sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2023, closing a stake of 32,352 shares — an estimated $83.8K sold.

Caxton Associates (New York) first reported a position in NGM in Q1 2023 and held it in 2 quarters. The position peaked at $170K in Q1 2023. 94 funds tracked by Wall St. Rank hold NGM as of Q3 2023.

  • Caxton Associates (New York) reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 32,352 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $83.8K.
  • Caxton Associates (New York) first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
  • Caxton Associates (New York)'s NGM Biopharmaceuticals, Inc. Common Stock position peaked at $170K in Q1 2023.
  • 94 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Caxton Associates (New York)'s 13F filing for Q3 2023, filed 14 Nov 2023.